US Edition
Immune Checkpoint Inhibitors in NSCLC: Do Survival Benefits End if Treatment Does? - ILCN.org (ILCN/WCLC)
Summary by ILCN.org (ILCN/WCLC)
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Immune Checkpoint Inhibitors in NSCLC: Do Survival Benefits End if Treatment Does? - ILCN.org (ILCN/WCLC)
Immune checkpoint inhibitors (ICIs) are largely considered a game-changer for patients with non-small cell lung cancer (NSCLC), delivering survival benefits in both early and advanced stages of the disease. However, between 3% and 12% of patients treated with a single ICI, and up to 25% of patients treated with immunotherapy combinations, must discontinue treatment due to immune-related adverse events (irAEs). Mark Awad, MD, PhD “When immunothe…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
